State-of-the-Art in Combination Immuno/Radiotherapy for Non-Small Cell Lung Cancer
Webinar | English | 1 Hr 13 Min
Image For Activity Cover
Credit Offered
No Credit Offered
This webinar will explore the expected benefits, toxicities and potential indications for the combination of immunotherapy and radiotherapy. Both are often used in the care of patients with non-small cell lung cancer, typically with non-overlapping indications for use. Topics will include the preclinical and clinical evidence and rationale for combining radiotherapy and immunotherapy. Target Audience: Physicians and researchers specializing in medical oncology, radiation oncology, pathology, pulmonary medicine and cancer research.
Faculty and Planners
  • Corinne Faivre-Finn, FRCR MD PhD discloses she receives research funding from Astra Zeneca, MSD Pharmaceuticals and Elekta and is on an advisory board and scientific committees for Astra Zeneca.
  • Shankar Siva, MBBS, FRANZCR, PhD discloses he is on an advisory board and is a consultant for Astra Zeneca and has a research grant from Varian Medical Systems.
  • Willemijn S.M.E. Theelen, MD PhD discloses she is an investigator for Astra Zeneca.
  • Kirsten Black, PhD, MPH has no financial relationships to disclose.
  • Aubrey Shoe, MA has no financial relationships to disclose.
At the end of the webinar, learners will be able to:
  • Understand the preclinical rationale for synergy in combining radiotherapy and immunotherapy.
  • Understand the unresolved questions around sequencing, dose/fractionation, abscopal effects, and sites of irradiation in combination therapy.
  • Understand pertinent clinical trial evidence for the safety and efficacy of radiotherapy and immunotherapy combinations.
  • Update key ongoing trials of RT-IO combo in the curative, oligometastatic and metastatic setting.
Powered By